<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32820020</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2332-7812</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>03</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title>
          <ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e841</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000841</ELocationID>
        <Abstract>
          <AbstractText>Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder that preferentially affects the spinal cord and optic nerve. Most patients with NMOSD experience severe relapses that lead to permanent neurologic disability; therefore, limiting frequency and severity of these attacks is the primary goal of disease management. Currently, patients are treated with immunosuppressants. Interleukin-6 (IL-6) is a pleiotropic cytokine that is significantly elevated in the serum and the CSF of patients with NMOSD. IL-6 may have multiple roles in NMOSD pathophysiology by promoting plasmablast survival, stimulating the production of antibodies against aquaporin-4, disrupting blood-brain barrier integrity and functionality, and enhancing proinflammatory T-lymphocyte differentiation and activation. Case series have shown decreased relapse rates following IL-6 receptor (IL-6R) blockade in patients with NMOSD, and 2 recent phase 3 randomized controlled trials confirmed that IL-6R inhibition reduces the risk of relapses in NMOSD. As such, inhibition of IL-6 activity represents a promising emerging therapy for the management of NMOSD manifestations. In this review, we summarize the role of IL-6 in the context of NMOSD.</AbstractText>
          <CopyrightInformation>Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fujihara</LastName>
            <ForeName>Kazuo</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan. fujikazu@med.tohoku.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bennett</LastName>
            <ForeName>Jeffrey L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Seze</LastName>
            <ForeName>Jerome</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haramura</LastName>
            <ForeName>Masayuki</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kleiter</LastName>
            <ForeName>Ingo</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-8249-4408</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weinshenker</LastName>
            <ForeName>Brian G</ForeName>
            <Initials>BG</Initials>
            <Identifier Source="ORCID">0000-0001-5806-6203</Identifier>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Delene</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mughal</LastName>
            <ForeName>Tabasum</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamura</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Multiple Sclerosis Therapeutics (K.F.), Fukushima Medical University School of Medicine; and Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan; Departments of Neurology and Ophthalmology (J.L.B.), Programs in Neuroscience and Immunology, School of Medicine, University of Colorado, Aurora; Department of Neurology (J.S.), Hôpital de Hautepierre, Strasbourg Cedex, France; Chugai Pharmaceutical Co. (M.H.), Ltd, Tokyo, Japan; Department of Neurology (I.K.), St. Josef Hospital, Ruhr University Bochum; Marianne-Strauß-Klinik (I.K.), Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany; Department of Neurology (B.G.W.), Mayo Clinic, Rochester, MN; ApotheCom (D.K., T.M.), London, UK; and Department of Immunology (T.Y.), National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 EY022936</GrantID>
            <Acronym>EY</Acronym>
            <Agency>NEI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA>
        <NlmUniqueID>101636388</NlmUniqueID>
        <ISSNLinking>2332-7812</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C508603">IL6R protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32820020</ArticleId>
        <ArticleId IdType="pmc">PMC7455314</ArticleId>
        <ArticleId IdType="doi">10.1212/NXI.0000000000000841</ArticleId>
        <ArticleId IdType="pii">7/5/e841</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tanaka T, Narazaki M, Kishimoto T. 
IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol
2014;6:a016295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4176007</ArticleId>
            <ArticleId IdType="pubmed">25190079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, et al. . 
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology
2015;85:177–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zekeridou A, Lennon VA. 
Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm
2015;2:e110
doi: 10.1212/NXI.0000000000000110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000110</ArticleId>
            <ArticleId IdType="pmc">PMC4442096</ArticleId>
            <ArticleId IdType="pubmed">26185772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadopoulos MC, Bennett JL, Verkman AS. 
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol
2014;10:493–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4229040</ArticleId>
            <ArticleId IdType="pubmed">25112508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan T, Smith AJ, Verkman AS. 
Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun
2019;7:112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6621951</ArticleId>
            <ArticleId IdType="pubmed">31296268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ataie-Kachoie P, Pourgholami MH, Morris DL. 
Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev
2013;24:163–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23107589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka T, Kishimoto T. 
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci
2012;8:1227–1236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3491446</ArticleId>
            <ArticleId IdType="pubmed">23136551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garbers C, Heink S, Korn T, Rose-John S. 
Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov
2018;17:395–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29725131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erta M, Quintana A, Hidalgo J. 
Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci
2012;8:1254–1266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3491449</ArticleId>
            <ArticleId IdType="pubmed">23136554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Q, Wang YI, Yang Y. 
Neuroprotective effect of interleukin-6 in a rat model of cerebral ischemia. Exp Ther Med
2015;9:1695–1701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4471691</ArticleId>
            <ArticleId IdType="pubmed">26136879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, Sadowska GB, Chen X, et al. . 
Anti-IL-6 neutralizing antibody modulates blood-brain barrier function in the ovine fetus. FASEB J
2015;29:1739–1753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4771067</ArticleId>
            <ArticleId IdType="pubmed">25609424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinshenker BG, Wingerchuk DM. 
Neuromyelitis spectrum disorders. Mayo Clin Proc
2017;92:663–679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28385199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Muto M, et al. . 
Benign neuromyelitis optica is rare in Japanese patients. Mult Scler
2015;21:1204–1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25480860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. 
The spectrum of neuromyelitis optica. Lancet Neurol
2007;6:805–815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitley J, Leite MI, Nakashima I, et al. . 
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain
2012;135:1834–1849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22577216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mealy MA, Kessler RA, Rimler Z, et al. . 
Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm
2018;5:e468
doi: 10.1212/NXI.0000000000000468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000468</ArticleId>
            <ArticleId IdType="pmc">PMC5994702</ArticleId>
            <ArticleId IdType="pubmed">29892608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Wingerchuk DM, Kryzer TJ, et al. . 
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet
2004;364:2106–2112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. 
Revised diagnostic criteria for neuromyelitis optica. Neurology
2006;66:1485–1489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16717206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowarik MC, Dzieciatkowska M, Wemlinger S, et al. . 
The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations. J Neuroinflammation
2015;12:19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4323273</ArticleId>
            <ArticleId IdType="pubmed">25626447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsdoerffer M, Kuchroo V, Korn T. 
Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci
2013;1283:57–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3963833</ArticleId>
            <ArticleId IdType="pubmed">23617588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Day RE, Kitchen P, Owen DS, et al. . 
Human aquaporins: regulators of transcellular water flow. Biochim Biophys Acta
2014;1840:1492–1506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24090884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Franciotta D, Paul F, et al. . 
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation
2010;7:52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2945323</ArticleId>
            <ArticleId IdType="pubmed">20825655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett JL, Lam C, Kalluri SR, et al. . 
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol
2009;66:617–629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3180961</ArticleId>
            <ArticleId IdType="pubmed">19938104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Wildemann B, et al. . 
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation
2012;9:14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3283476</ArticleId>
            <ArticleId IdType="pubmed">22260418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Kleiter I, et al. . 
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation
2016;13:280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5086042</ArticleId>
            <ArticleId IdType="pubmed">27793206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu F, Schaller KL, Owens GP, et al. . 
Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci Transl Med
2017;9:eaai9111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5585784</ArticleId>
            <ArticleId IdType="pubmed">28679661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nytrova P, Potlukova E, Kemlink D, et al. . 
Complement activation in patients with neuromyelitis optica. J Neuroimmunol
2014;274:185–191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25109258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tradtrantip L, Yao X, Su T, Smith AJ, Verkman AS. 
Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol
2017;134:35–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5600280</ArticleId>
            <ArticleId IdType="pubmed">28567523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao X, Verkman AS. 
Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun
2017;5:57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5532786</ArticleId>
            <ArticleId IdType="pubmed">28750658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamvil SS, Spencer CM, Baranzini SE, Cree BAC. 
The gut microbiome in neuromyelitis optica. Neurotherapeutics
2018;15:92–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5794705</ArticleId>
            <ArticleId IdType="pubmed">29280091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omenetti S, Pizarro TT. 
The Treg/Th17 Axis: a dynamic balance regulated by the gut microbiome. Front Immunol
2015;6:639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4681807</ArticleId>
            <ArticleId IdType="pubmed">26734006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Masuda H, et al. . 
Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica. Clin Chim Acta
2017;469:144–149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28283439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Wang K, Zhong X, et al. . 
Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation
2012;19:304–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22777162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Arai K, et al. . 
Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler
2010;16:1443–1452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20739337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uchida T, Mori M, Uzawa A, et al. . 
Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption. Mult Scler
2017;23:1072–1084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27682231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita T, Tateishi T, Isobe N, et al. . 
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One
2013;8:e61835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3630114</ArticleId>
            <ArticleId IdType="pubmed">23637915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Icoz S, Tuzun E, Kurtuncu M, et al. . 
Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci
2010;120:71–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20128675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barros PO, Cassano T, Hygino J, et al. . 
Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol
2016;183:480–489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4750605</ArticleId>
            <ArticleId IdType="pubmed">26472479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Ito M, et al. . 
Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol
2009;256:2082–2084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19655191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Sawai S, et al. . 
Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta
2013;421:181–183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23535508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S. 
CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry
2012;83:339–340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21429904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chihara N, Aranami T, Sato W, et al. . 
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA
2011;108:3701–3706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3048150</ArticleId>
            <ArticleId IdType="pubmed">21321193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowarik MC, Astling D, Gasperi C, et al. . 
CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol
2017;4:369–380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5454399</ArticleId>
            <ArticleId IdType="pubmed">28589164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dienz O, Eaton SM, Bond JP, et al. . 
The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med
2009;206:69–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2626667</ArticleId>
            <ArticleId IdType="pubmed">19139170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dos Passos GR, Sato DK, Becker J, Fujihara K. 
Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications. Mediators Inflamm
2016;2016:5314541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4749822</ArticleId>
            <ArticleId IdType="pubmed">26941483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HH, Dai YQ, Qiu W, et al. . 
Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci
2011;18:1313–1317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21795048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. . 
Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol
2012;72:53–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3405197</ArticleId>
            <ArticleId IdType="pubmed">22807325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshita Y, Obermeier B, Cotleur AC, et al. . 
Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm
2017;4:e311
doi: 10.1212/NXI.0000000000000311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000311</ArticleId>
            <ArticleId IdType="pmc">PMC5173350</ArticleId>
            <ArticleId IdType="pubmed">28018943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujihara K, Sato DK, Nakashima I, et al. . 
Myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease: an overview. Clin Exp Neuroimmunol
2018;9:48–55.</Citation>
        </Reference>
        <Reference>
          <Citation>Kaneko K, Sato DK, Nakashima I, et al. . 
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry
2016;87:1257–1259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26800711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree BAC, Bennett JL, Kim HJ, et al. . 
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet
2019;394:1352–1363.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31495497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, et al. . 
Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med
2019;381:614–625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamura T, Kleiter I, Fujihara K, et al. . 
Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med
2019;381:2114–2124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31774956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringelstein M, Ayzenberg I, Harmel J, et al. . 
Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol
2015;72:756–763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25985228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauenstein AS, Stettner M, Kieseier BC, Lensch E. 
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab. BMJ Case Rep
2014;2014:bcr2013202939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3975485</ArticleId>
            <ArticleId IdType="pubmed">24671322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M, Matsuoka T, Miyamoto K, et al. . 
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology
2014;82:1302–1306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4001188</ArticleId>
            <ArticleId IdType="pubmed">24634453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kieseier BC, Stuve O, Dehmel T, et al. . 
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol
2013;70:390–393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23599943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayzenberg I, Kleiter I, Schroder A, et al. . 
Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol
2013;70:394–397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23358868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. 
Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol
2013;23:827–831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3713263</ArticleId>
            <ArticleId IdType="pubmed">22782533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harmel J, Ringelstein M, Ingwersen J, et al. . 
Interferon-beta-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurol
2014;14:247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4301061</ArticleId>
            <ArticleId IdType="pubmed">25516429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Traboulsee A, Greenberg B , Bennett JL, et al. . 
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol
2020;19:402–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32333898</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
